Anti-Mouse CD49d – Dylight® 650

AKR/Cum mouse Spontaneous T lymphoma line TK1

This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

R1-2 activity is directed against mouse CD49d.

Integrins are a large family of heterodimeric transmembrane molecules that mediate adhesion, migration, cell survival, and cell differentiation. CD49d is a single-pass type I membrane glycoprotein also known as integrin alpha-4 (Uniprot Accession P13612). CD49d is the α4 subunit of integrin heterodimers alpha-4/beta-1 (VLA-4; CD49d/CD29; α4β1 integrin) and alph-4/beta-7 (LPAM-1)¹. These integrins act as receptors for fibronectin and VCAM1 (CD106). Integrin alpha-4/beta-7 is also a receptor for MADCAM1.

CD49d is expressed on most lymphocytes, granulocytes, monocytes, and thymocytes. CD49d/CD29 (VLA-4; α4β1) is expressed at high levels on the surface of lymphohematopoietic progenitors and is involved in their development and proliferation. CD49d/CD29 integrin/VCAM-1 interactions facilitate B cell adhesion to stromal cells and enhance B cell activation. In the absence of alpha-4 integrins, pre-B cells fail to transmigrate and proliferate.

R1-2 was generated by immunizing Fisher rats with TK1, a Peyer’s patch high endothelial venules (HEV) binding lymphoma line². Spleen cells were subsequently fused with nonsecreting mouse myeloma P3x63Ag8.653 cells. Hybridomas producing antibodies reactive with TK1 cells, but not the HEV nonbinding lymphoma TK5, were cloned and screened for inhibition of lymphocyte binding to HEV of either peripheral nodes or Peyer’s patches.

CD49d is expressed on T cells, B cells, NK cells, dendritic cells, thymocytes, monocytes, eosinophils, mast cells.

VCAM-1, MAdCAM-1, fibronectin

1. Holzmann B, Weissman IL. EMBO J. 8(6):1735-1741. 1989.
2. Holzmann B, McIntyre BW, Weissman IL. Cell. 56(1):37-46. 1989.
3. Jin H, Aiyer A, Su J, et al. J Clin Invest. 116(3):652-662. 2006.
4. DeNucci CC, Pagán AJ, Mitchell JS, et al. J Immunol. 184(5):2458-2467. 2010.
5. Uchida Y, Kawai K, Ibusuki A, et al. J Immunol. 186(12):6945-6954. 2011.
6. Hadeiba H, Lahl K, Edalati A, et al. Immunity. 36(3):438-450. 2012.
7. Shokeen M, Zheleznyak A, Wilson JM, et al. J Nucl Med. 53(5):779-786. 2012.
8. Renkema KR, Li G, Wu A, et al. J Immunol. 192(1):151-159. 2014.
9. Hermida MD, Doria PG, Taguchi AM, et al. BMC Infect Dis. 14:450. 2014.
10. Mamedov MR, Scholzen A, Nair RV, et al. Immunity. 48(2):350-363.e7. 2018.
11. Rolot M, Dougall AM, Chetty A, et al. Nat Commun. 9(1):4516. 2018.
12. Martin MD, Sompallae R, Winborn CS, et al. Cell Rep. 31(2):107508. 2020.
13. Müller K, Gibbins MP, Roberts M, et al. EMBO Mol Med. 13(4):e13390. 2021.
14. Barrett SP, Riordon A, Toh BH, et al. J Leukoc Biol. 67(2):169-173. 2000.
15. Lin J, Qin L, Chavin KD, et al. Pathobiology. 63(3):119-132. 1995.
16. Chisholm PL, Williams CA, Lobb RR. Eur J Immunol. 23(3):682-688. 1993.